Free Trial

Bio-Rad Laboratories (NYSE:BIO.B) Sets New 12-Month Low - Should You Sell?

Bio-Rad Laboratories logo with Medical background
Remove Ads

Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report)'s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $241.99 and last traded at $241.99, with a volume of 110 shares traded. The stock had previously closed at $265.82.

Bio-Rad Laboratories Stock Performance

The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The firm has a market cap of $6.78 billion, a P/E ratio of -3.72 and a beta of 0.75. The business has a fifty day simple moving average of $298.19 and a 200-day simple moving average of $321.85.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.90 earnings per share for the quarter. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%.

About Bio-Rad Laboratories

(Get Free Report)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Recommended Stories

Should You Invest $1,000 in Bio-Rad Laboratories Right Now?

Before you consider Bio-Rad Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.

While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

5 Stocks to BUY Now as Tariff Uncertainty Fades
WWE Stock Could Explode Next Week — Now’s the Time to Buy Into TKO
These 3 Dividend Stocks Might Be the Safest Bet Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads